Sandbox vidit3: Difference between revisions
No edit summary |
No edit summary |
||
Line 292: | Line 292: | ||
<div class="mw-collapsible mw-collapsed" id="mw-customcollapsible-box8" style="background: #B8B8B8; padding: 5px 10px;"> | <div class="mw-collapsible mw-collapsed" id="mw-customcollapsible-box8" style="background: #B8B8B8; padding: 5px 10px;"> | ||
'''Confirm diagnosis of syncope''' <br> ''Must have this 3 characteristics:'' <br> | '''Confirm diagnosis of syncope''' <br> ''Must have this 3 characteristics:'' <br> ❑ Short duration <br> ❑ Rapid onset <br> ❑ Complete spontaneous recovery | ||
</div> | </div> | ||
Revision as of 17:38, 26 March 2014
New
Click on boxes to expand/collapse detailed information.
|
❑ Prodrome:
❑ Chest pain (suggestive of cardiovascular syncope)
❑ Activity prior to LOC: (suggestive of cardiovascular or reflex syncope)
❑ Bowel or bladder incontinence (suggestive of reflex syncope) Inquire about medications intake:
Obtain a detailed past medical history:
❑ Cardiovascular disease:
❑ Neurological diseases: ❑ Metabolic disorders (diabetes) ❑ Recent trauma
Identify possible triggers: Suggestive of cardiovascular or orthostatic hypotension
Examine the patient
Vitals
Respiratory Cardiovascular
Neurologic
❑ Glasgow coma scale
Order labs and tests
❑ Glucose (rule out hypoglycemia)
Confirm diagnosis of syncope
Diagnostic criteria
❑ Cardiovascular
❑ Orthostatic hypotension (OH)
❑ Reflex
Determine if there are any high risk criteria:
❑ Important comorbidities:
Consider alternative diagnoses:
|
Drug | Adult dosage |
---|---|
Inhaled Short Acting β Agonists (SABA) | |
Albuterol/Bitolterol/Pirbuterol a) Nebulizer solution b) MDI | ♦ 2.5-5 mg every 20 minutes for 3 doses, then 2.5-10 mg every 1-4 hours as needed or 10-15 mg/hour continuously. ♦ 4-8 puffs every 20 mins upto 4 hours, then every 1-4 hours as needed. |
Levalbuterol a) Nebulizer solution b) MDI | ♦ 1.25-2.5 mg every 20 mins for 3 doses, then 1.25-5 mg every 1-4 hours as needed. ♦ 4-8 puffs every 20 mins upto 4 hours, then every 1-4 hours as needed. |
Anticholinergics | |
Ipratropium bromide a) Nebulizer solution b) MDI | ♦ 0.5 mg every 20 mins for 3 doses, then as needed. ♦ 8 puffs every 20 mins as needed for upto 3 hours. |
Ipratropium with albuterol a) Nebulizer solution (each 3 ml containing 0.5 mg ipratropium and 2.5 mg albuterol) b) MDI (each puff contains 18 mcg ipratropium and 90 mcg albuterol) | ♦ 3 ml every 20 mins for 3 doses, then as needed. ♦ 8 puffs every 20 mins as needed for 3 hours |
Systemic corticosteroids | |
Prednisone/Prednisolone/Methylprednisolone | ♦ 40-80 mg/day in 1 or 2 divided doses until peak expiratory flowrate (PEF) reaches 70% of personal best. |
Clinical course | Unstable |
---|---|
Physical examination | Signs of heart failure |
Functional class | IV |
6MWD | Less than 400 m |
Echocardiogram | RV Enlargement |
Hemodynamics | RAP high CI low |
BNP | Elevated/Increasing |
Treatment | Intravenous prostacyclin and/or combination treatment |
Frequency of evaluation | Q 1 to Q 3 months |
FC assessment | Every clinic visit |
6MWT | Every clinic visit |
Echocardiogram2 | Q 6 to Q 12 months/center dependent |
BNP | center dependent |
RHC | Q 6 to Q 12 months or clinical deterioration |